Exciting Data on Atopic Dermatitis from EADV 2024
Professor April Armstrong highlights new advancements in atopic dermatitis treatments. Lebrikizumab proved safe and effective in older patients, while tralokinumab reduced symptoms in high-impact areas like the face. Promising new treatments, including OX40 inhibitors, are on the horizon. Additionally, topical JAK inhibitors like delgocitinib show similar efficacy to systemic therapies like dupilumab for chronic hand eczema.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in